Clinical trials: Proton Radiotherapy
HCC - Hepatocellular Carcinoma, Durvalumab
Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Tremelimumab plus durvalumab (STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), yet it shows limited efficacy with an ORR of only 20.1%.
- Conditions
- HCC - Hepatocellular Carcinoma, Durvalumab, Tremelimumab, Proton Radiotherapy
- Trial name
- Proton-STRIDE (NCT06999694)
- Testing
- Proton radiotherapy, Tremelimumab, Durvalumab
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
Cavernous Sinus Meningioma, Proton-therapy
Long-term Cognitive and Functional Impact of Proton-therapy or Modern Fractionated Radiotherapy in Cavernous Sinus Meningioma: An Open-label Randomized 1:1 Phase III Study
Cavernous sinus meningiomas are close to optic nerve, pituitary gland, cranial nerve, and hippocampi. The doses delivered to these structures are crucial and radiotherapy of cavernous sinus meningiomas exposes patients to late…
- Conditions
- Cavernous Sinus Meningioma, Proton-therapy, Photon Radiotherapy, Cognitive Impairment
- Trial name
- COG-PROTON-01 (NCT05895344)
- Testing
- Proton-therapy, Photon radiotherapy
- Where
- 13 sites in France
- Volunteers
- 160 people
- Sponsor
- Centre Francois Baclesse
Paramedical Consultation, Radiotherapy
Interest of a Weekly Consultation by a Medical Electro Radiology Manipulator (MERM) in Addition to the Follow-up by the Radiotherapist to Improve the Collection of Radio-induced Toxicities in Patients Undergoing Proton Therapy
To our knowledge, the investigators have not found any scientific article dealing with cooperation between radiation oncologists and medical radiation technologists in the context of monitoring patients undergoing radiotherapy.
- Conditions
- Paramedical Consultation, Radiotherapy, Proton Therapy, Brain Tumor
- Trial name
- MERMOSE (NCT05404308)
- Testing
- Consultation with Manipulator in Medical Radiology and a radiotherapist, Consultation with a radiotherapist
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Centre Francois Baclesse
Thymus Epithelial Tumor, Proton Radiotherapy
The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor
To observe the efficacy and toxicities of post-operative (R0/R1) proton radiotherapy for locally advanced primary thymus epithelial malignancies.
- Conditions
- Thymus Epithelial Tumor, Proton Radiotherapy, Radiation Toxicity
- Trial name
- NCT06311968
- Testing
- Proton radiotherapy, combined platinum based chemotherapy
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Jian Chen
Breast Cancer, Proton Therapy
Safety and Efficacy of IMPT or IMRT for Breast Cancer
The purpose of this trial is to compare the toxicities and efficacy of intensity-modulated proton therapy (IMPT) and intensity-modulated radiation therapy (IMRT) for breast cancer patients indicated for radiotherapy including…
- Conditions
- Breast Cancer, Proton Therapy, Intensity Modulated Radiation Therapy, Efficacy and Safety
- Trial name
- SEPPT-BC (NCT06826885)
- Testing
- Postoperative radiotherapy, Preoperative Radiotherapy, Definitive Radiotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Esophageal Cancer, Radiotherapy
PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy
The PROTECT trial will test the hypothesis that proton (PT) -enabled radiation dose reductions to sensitive, normal tissues will result in lower rates of treatment-related pulmonary complications in esophageal cancer compared to…
- Conditions
- Esophageal Cancer, Radiotherapy, Side Effect, Proton Therapy
- Trial name
- PROTECT (NCT05055648)
- Testing
- Photon Radiotherapy, Proton Radiotherapy
- Where
- 15 sites in Belgium, Denmark and 6 more
- Volunteers
- 396 people
- Sponsor
- University of Aarhus
Cervical Cancer, Proton Therapy
Proton Therapy for Locally Advanced Cervical Cancer
The purpose of this protocol is to determine toxicity and efficacy of proton therapy in combination with standard concomitant platinum-based chemotherapy and standard image-guided adaptive brachytherapy (IGABT) in patients with…
- Conditions
- Cervical Cancer, Proton Therapy, Radiotherapy Side Effect
- Trial name
- NCT06462378
- Testing
- Proton therapy
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- University of Aarhus
Head and Neck Squamous Cell Carcinoma, Hypofractionation
HYpofractionated, Dose-redistributed RAdiotherapy With Protons and Photons in HNSCC
Radiotherapy for advanced-stage head and neck squamous cell carcinoma (HNSCC) results in an unfavorable 5-year overall survival of 40%, and there is a strong biological rationale for improving outcome by combinatorial treatment…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Hypofractionation, Radiotherapy, Proton Therapy
- Trial name
- HYDRA (NCT05364411)
- Testing
- HYpofractionated, Dose-redistributed RAdiotherapy (HYDRA), conventional fractionated radiotherapy
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Joris B.W. Elbers